Urinary excretory processes in men with urolithiasis treated during the pandemic of COVID-19

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Androgen deficiency can boost stone formation in kidneys, therefore androgen replacement therapy is successfully used in the treatment of patients with urolithiasis on the background of androgen deficiency. There are numerous publications describing the work of urologists during COVID-19 pandemics however they are all devoted to organization of medical aid. Increased risk of urolithiasis during COVID infection is mentioned as well as the general decrease of physical activity during COVID and general decrease of life quality. On the other hand, the direct effect of androgen deficit not to mention the influence of augment androgen therapy on the background of COVID has never been studied.

AIM: The aim of this work was to find out the possibility of using this type of therapy in the treatment in the conditions of COVID-19 pandemic as far as electrolyte metabolism and urinary excretion processes — the central links in the pathogenesis of urolithiasis.

MATERIALS AND METHODS: 199 male patients age 25 through 68 years were studied while under treatment at Urologic Dept. of St. Elisabeth Clinical Hospital in Saint Petersburg. Laboratory and clinical parameters were registered at he beginning of stationary treatment, after in ended and also in 4 and 12 months. Some of реу studies were accomplished in triplets skipping the moment of discharge from the hospital. Out of 99 patients received only traditional therapy (contact ureterolitotripsy after distant litotripsy) while 100 patients got androgenous replacement therapy.

RESULTS: Based on the results of treatment of 199 men suffering from urolithiasis, it was found that COVID-19 infection did not create fundamental contraindications for the use of androgen replacement therapy in the treatment of urolithiasis.

CONCLUSION: In patients with urolithiasis suffering from COVID-19 infection and receiving androgen replacement therapy, there was no additional increase in pathologic processes associated with the underlying disease, i.e., androgen replacement therapy was not contraindicated, therefore in case of pandemic recurrence, androgen replacement therapy can be used in the treatment of urolithiasis.

Full Text

Restricted Access

About the authors

Zaur K. Emirgaev

Saint Petersburg State Pediatric Medical University; St. Elizabeth City Hospital

Email: zaur.emirgaev@mail.ru
SPIN-code: 6771-7532

Postgraduate Student, Pathophysiology Department, Saint Petersburg State Pediatric Medical University, Ministry of Health of the Russian Federation

Russian Federation, Saint Petersburg; Saint Petersburg

Nair S. Tagirov

Saint Petersburg State Pediatric Medical University; St. Elizabeth City Hospital

Email: ruslana73nair@mail.ru
ORCID iD: 0000-0002-4362-3369
SPIN-code: 9810-1650

MD, PhD, Dr. Sci. (Medicine), Professor, Pathophysiology Department, Saint Petersburg State Pediatric Medical University, Ministry of Health of Russian Federation

Russian Federation, Saint Petersburg; Saint Petersburg

Andrei G. Vasiliev

Saint Petersburg State Pediatric Medical University

Author for correspondence.
Email: avas7@mail.ru
ORCID iD: 0000-0002-8539-7128
SPIN-code: 1985-4025

MD, PhD, Dr. Sci. (Medicine), Professor, Head of Pathophysiology Department

Russian Federation, Saint Petersburg

Anna V. Vasilieva

Saint Petersburg State Pediatric Medical University

Email: a-bondarenko@yandex.ru
ORCID iD: 0009-0008-2356-1552
SPIN-code: 5333-0144

Assistant Professor, Department of Pathological Physiology with the Course of Immunopathology

Russian Federation, Saint Petersburg

References

  1. Vasilyev AG, Tahirov NS, Nazarov TH, et al. Modern aspects of the etiology and pathogenesis of urolithiasis. Pediatrician (St. Petersburg). 2014;5(3):101–109. doi: 10.17816/PED53101-109 EDN: STDBSP
  2. Komyakov BK, Akimov AN, Tagirov NS, et al. Percutaneous nephrolithotomy in the treatment of urolithiasis in patients with hypogonadism. In: Collection of articles in honor of the 35th anniversary of Elizavetinskaya hospital. Saint Petersburg; 2017. P. 170–174. (In Russ.)
  3. Komiakov BK, Vasiliev AG, Guliev BG, et al. Androgen replacement administration in patients with hypogonadism and urolithiasis. In: Actual issues of urology and andrology. 2011. P. 66–69. (In Russ.)
  4. Komyakov BK, Akimov AN, Tagirov NS, et al. Correction of hypogonadism in patients with urolithiasis. In: Collection of articles in honor of the 35th anniversary of Elizavetinskaya hospital. Saint Petersburg; 2017. P. 154–157. (In Russ.)
  5. Nazarov TKh, Guliev BG, Stetsik OV, et al. Diagnostics and correction of metabolic disorders in patients with recurrent urolithiasis after endoscopic removal of stones. Andrology and Genital Surgery. 2015;16(3):22–28. doi: 10.17650/2070-9781-2015-16-3-22-28 EDN: ULHBXH
  6. Smirnova NN, Kuprienko NB. Uromodulin and its role in the formation of renal components in children and adolescents. Children’s medicine of the North-West. 2022;10(1):44–48. EDN: AEEUCA
  7. Lemeshko BB, Lemeshko SB, Postovalov SN, Chimitova EV. Statistical data analysis, modeling and study of probabilistic patterns. Computer approach. Novosibirsk: NSTU; 2011. 888 p. EDN: TZNHMX (In Russ.)
  8. Tagirov NS, Haitsev NV, Nazarov TH, et al. The significance of androgenous deficiency in pathogenesis of urolithiasis: experimental and clinical studies. Clinical Pathophysiology. 2016;22(1):107–112. EDN: WAHDYD
  9. Tagirov NS. Effectiveness of nephrolithiasis surgical treatment on the background of replacement testosterone therapy. Pediatrician (St. Petersburg). 2019а;10(2):46–54. doi: 10.17816/PED10247-54 EDN: EUXYNH
  10. Tagirov NS. Pathogenetic correction of metabolic disorders and androgen deficiency in the treatment of patients with urolithiasis (clinical and experimental study) [dissertation abstract]. Saint Petersburg; 2019. Available from: https://vmeda.mil.ru/upload/site56/document_file/h5OPaCxTzp.pdf (In Russ.)
  11. Emirgaev ZK, Tagirov NS, Vasilyev AG, Emirgaev OK. Status of hemostatic system in men with urolithiasis treated under during COVID-19 pandemic. Russian Biomedical Research. 2024;9(3):28–34. doi: 10.56871/RBR.2024.90.67.004 EDN: IRVPYE
  12. Aleebrahim-Dehkordi E, Soleiman-Dehkordi E, Saberianpour S, et al. Care and prevention during the COVID-19 pandemic quarantine: sedentary lifestyle and increased risk of kidney stones. Przegl Epidemiol. 2021;75(1):45–50. doi: 10.32394/pe.75.04
  13. El-Achkar TM, Wu XR, Rauchman M, et al. Tamm–Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Renal Physiol. 2008;295(2):F534–F544. doi: 10.1152/ajprenal.00083.2008
  14. Gul M, Kaynar M, Yildiz M, et al. The increased risk of complicated ureteral stones in the era of COVID-19 pandemic. J Endourol. 2020;34(8): 882–886. doi: 10.1089/end.2020.0658
  15. Harke NN, Radtke JP, Hadaschik BA, et al. To defer or not to defer? A German longitudinal multicentric assessment of clinical practice in urology during the COVID-19 pandemic. PLoS One. 2020;15(9):e0239027. doi: 10.1371/journal.pone.0239027
  16. Nakagawa Y. Properties and function of nephrocalcin: mechanism of kidney stone inhibition or promotion. Keio J Med. 1997;46(1):1–9. doi: 10.2302/kjm.46.1
  17. Nourian A, Uppaluri C, Chen M, et al. Comparison of management and outcomes of symptomatic urolithiasis during the COVID-19 pandemic to a comparative cohort. Urology. 2022;165:178–183. doi: 10.1016/j.urology.2022.01.019
  18. Vazzana N, Dipaola F, Ognibene S. Procalcitonin and secondary bacterial infections in COVID-19: association with disease severity and outcomes. Acta Clin Belg. 2022;77(2):268–272. doi: 10.1080/17843286.2020.1824749
  19. Wong VKF, Bhojani N, Bird V, et al. Quality of life of urolithiasis patients during the COVID-19 pandemic: A multi-institutional cross-sectional study. J Endourol. 2022;36(6):798–806. doi: 10.1089/end.2021.0298
  20. Xiao N, Xie Z, He Z, et al. Pathogenesis of gout: Exploring more therapeutic target. Int J Rheum Dis. 2024;27(4): e15147. doi: 10.1111/1756-185X.15147
  21. Zhu W, Liu Y, Lan Y, et al. Dietary vinegar prevents kidney stone recurrence via epigenetic regulations. EBioMedicine. 2019;45:231–250. doi: 10.1016/j.ebiom.2019.06.004

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Procalcitonin concentration in peripheral blood of patients treated for urolithiasis with conventional treatment (a) or androgen replacement therapy (b). C(+) with COVID-19, C(–) without COVID-19. Stages of follow-up: 0, at the beginning of treatment; 1, at the time of hospital discharge; 4, after 4 months; 12, after 12 months. Mean ± standard deviation are presented.

Download (106KB)
Indexing metadata
3. Fig. 2. Total calcium concentration in the blood of patients treated for urolithiasis with conventional treatment (a) or androgen replacement therapy (b). C(+) with COVID-19, C(–) without COVID-19. Other designations are the same as in Fig. 1.

Download (116KB)
Indexing metadata
4. Fig. 3. Mg2+ concentration in the blood of patients receiving conventional treatment (a) or androgen replacement therapy (b) for urolithiasis. C(+) with COVID-19, C(–) without COVID-19. Other designations are the same as in Fig. 1.

Download (113KB)
Indexing metadata
5. Fig. 4. Urinary magnesium excretion in patients receiving conventional treatment (a) or androgen replacement therapy (b) for urolithiasis. C(+) with COVID-19, C(–) without COVID-19. Other designations are the same as in Fig. 1.

Download (119KB)
Indexing metadata
6. Fig. 5. Uromodulin or Tamm–Horsfall protein concentration in urine (mg/L) of patients receiving conventional treatment (a) or androgen replacement therapy (b) for urolithiasis. C(+) with COVID-19, C(–) without COVID-19. Other designations are the same as in Fig. 1.

Download (115KB)
Indexing metadata

Copyright (c) 2025 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 69634 от 15.03.2021 г.